What Is Menopausal Hormone Therapy?

What is menopausal hormone therapy, in plain English?

Menopausal hormone therapy is prescription medicine that uses estrogen — and, for many people, progesterone or a similar hormone — to relieve symptoms caused by the hormone drop of menopause. It's most often used for hot flashes, night sweats, and vaginal symptoms, and sometimes to help prevent bone loss. The better question isn't “is MHT good or bad,” but “which type, for which symptom, in which person.”

Sources: FDA, 2026; Mayo Clinic, 2025; The Menopause Society, 2022.

As you move through the menopause transition, your ovaries wind down and your estrogen and progesterone levels fall. Those falling levels are behind a lot of the classic symptoms — the heat that hits out of nowhere, the 3 a.m. sweats, the dryness, the sleep that won't hold. MHT works by adding some of those hormones back, in a form and dose a clinician picks for you.

A quick word, if you're feeling nervous

A lot of people land on this page a little scared. For twenty years, these drugs carried the scariest warning label the FDA gives. We'll walk through where that fear came from and what the science actually says.

The words people use — decoded

The biggest source of confusion isn't the medicine. It's the vocabulary. People hear MHT, HRT, HT, “bioidentical,” and “body-identical,” and assume they're all different things. Mostly, they're not.

The HRT Index Naming Decoder

Notice the last two. “Bioidentical” and “compounded” get blended together constantly — even though they mean completely different things. Sorting that out is one of the most useful things this page can do for you, and we get into it in depth below.

What MHT is not

MHT is not an anti-aging treatment. It's not a weight-loss drug. It's not automatically “safer” because someone slapped the word “natural” or “bioidentical” on it. And it's not right for everyone. Anyone selling it as a fountain of youth is selling, not informing.

What symptoms does menopausal hormone therapy treat?

MHT is mainly used for bothersome menopause symptoms: hot flashes, night sweats, vaginal dryness, and pain with sex. Whole-body (systemic) estrogen treats whole-body symptoms like hot flashes. Low-dose vaginal estrogen treats local symptoms like dryness and isn't meant for hot flashes. MHT can also help prevent bone loss in certain people. The Menopause Society calls hormone therapy the most effective treatment available for hot flashes and night sweats.

Sources: The Menopause Society, 2022; Mayo Clinic, 2025; FDA, 2026.

The single most useful idea here: match the symptom to the route. Where your symptoms are tells you which kind of MHT a clinician is likely to talk about.

The HRT Index Symptom-to-Route Map

Two medical terms you'll run into, defined once:

• Vasomotor symptoms (VMS) is just the medical name for hot flashes and night sweats.
• Genitourinary syndrome of menopause (GSM) is the medical name for vaginal and urinary changes — dryness, irritation, pain with sex, more frequent UTIs.

Where the gray areas are

People often ask whether MHT fixes brain fog, mood, weight, or sleep. The honest answer is “sometimes, indirectly.” If your night sweats stop, you sleep better — and better sleep helps mood and focus. But MHT is not an approved treatment for depression, anxiety, weight loss, or anti-aging.

What are the main types of menopausal hormone therapy?

For a beginner, there are three practical types: estrogen-alone therapy (usually for people without a uterus), estrogen plus a progestogen (for people who still have a uterus), and low-dose vaginal estrogen (for local symptoms only). Within those, you can take hormones as a pill, patch, gel, spray, vaginal ring, cream, or tablet. The best type depends on your symptoms, your uterus status, your health history, and your preference.

Sources: FDA, 2026; Mayo Clinic, 2025.

Type 1: Estrogen-alone therapy

Estrogen by itself. This is typically discussed for people who've had a hysterectomy (surgery to remove the uterus). No uterus usually means no need for the second hormone — we explain exactly why in the progesterone section.

Type 2: Estrogen plus a progestogen

Estrogen and a second hormone — progesterone or a man-made version called a progestin (the umbrella word for both is progestogen). This combo is the standard discussion for people who still have a uterus and want whole-body symptom relief. The progestogen's main job: protecting the lining of the uterus.

Type 3: Low-dose vaginal estrogen

A small amount of estrogen placed right where it's needed — as a cream, tablet, ring, or insert — for vaginal and urinary symptoms. Because the dose is low and local, very little estrogen reaches the rest of your body. That's a key reason it's treated differently from whole-body therapy.

How you take it: the delivery method matters

Same hormone, different doorway into your body — and the doorway can change the risk picture.

The HRT Index Delivery Method Guide

Where does testosterone fit?

Testosterone sometimes comes up for low sex drive after menopause when estrogen therapy alone hasn't helped. Two facts matter: First, there is no FDA-approved testosterone product for women — any use is “off-label.” (Source: ACOG.) Second, testosterone is a Schedule III controlled substance in the United States — it legally requires a prescription and proper medical supervision. Anyone offering it casually or as a shortcut is a red flag.

Bioidentical, body-identical, compounded — what's the real difference?

“Bioidentical” describes a hormone whose structure matches what your body makes — it is not a measure of safety or quality. Some bioidentical hormones, like estradiol and micronized progesterone, are FDA-approved. “Compounded” hormones are mixed to order by a pharmacy and are not FDA-approved, which means the FDA does not check their safety, effectiveness, or quality before they're sold. “Bioidentical” and “compounded” are not the same thing.

Sources: ACOG; FDA; NCI.

The HRT Index Bioidentical Clarity Table

Read the middle row again: you do not have to choose between “bioidentical” and “FDA-approved.” Plenty of FDA-approved products arebioidentical. The two ideas aren't opposites.

Compounded drugs are not FDA-approved, which means the FDA does not verify their safety, effectiveness, or quality before they go on the market. (Source: FDA.) And the National Cancer Institute says claims that non-FDA-approved “bioidentical” products are safer or more natural are not backed by credible scientific evidence. (Source: NCI.)

If a provider tells you a compounded hormone is “clinically proven,” “FDA-approved,” “the same as” an approved drug, or simply “safer” — those claims aren't supported, and that's your cue to ask harder questions.

Do you need progesterone if you still have a uterus?

If you still have a uterus and take systemic (whole-body) estrogen, a clinician will almost always add progesterone or a progestogen to protect your uterine lining. Estrogen on its own can thicken that lining and raise the risk of endometrial (uterine) cancer. If you've had a hysterectomy, you usually don't need a progestogen with estrogen — but your clinician should confirm.

Sources: Mayo Clinic, 2025; NCI; FDA, 2026.

Here's the simple logic:

• Estrogen tells the uterine lining to grow. That's its normal effect.
• Unopposed estrogen — estrogen with nothing to balance it — can let that lining build up too much over time, raising endometrial cancer risk.
• A progestogen keeps the lining in check. It's the counterweight. That's the whole reason it's there.

The HRT Index Uterus Rule

When the FDA overhauled the warning labels in 2026, the one boxed warning it specifically kept was the endometrial-cancer warning for systemic estrogen-alone products. (Source: Society of Gynecologic Oncology; FDA, 2026.)Even as regulators eased many old warnings, this risk stayed front and center. If you're not 100% sure of your own uterus status, that's the first thing to nail down with a clinician.

Is menopausal hormone therapy safe?

MHT can be safe and appropriate for many people, but “safe” depends on the person — your age, how long it's been since menopause, your health history, and the dose, route, and type of hormone. The Menopause Society says that for most healthy women under 60, or within 10 years of menopause, with no reasons to avoid it, the benefits generally outweigh the risks.

Sources: The Menopause Society, 2022; Mayo Clinic, 2025.

Timing is the big one: the “window of opportunity”

This is the single most important safety concept in modern menopause care. The benefit-and-risk math shifts depending on when you start.

The HRT Index Timing Window Framework

The other things that move the needle

• Route. Skin-based estrogen and lower doses may carry lower clot and stroke risk than pills. (Source: The Menopause Society, 2022.)
• Uterus status. Estrogen alone vs. estrogen-plus-progestogen — the endometrial protection question from the last section.
• Your personal history. A history of certain cancers, blood clots, stroke, heart attack, or liver disease changes everything. More on that in who should wait.
• “Lowest effective dose.” Enough to control your symptoms, no more, checked over time.

Where the fear actually came from (and why it was overcorrected)

In 2002, a large U.S. study called the Women's Health Initiative (WHI) was stopped early when it found higher risks of breast cancer and stroke in one group of users. Starting in 2003, the FDA added its strongest “boxed” warnings to these drugs — where they stayed for over twenty years. (Sources: NCI; Contemporary OB/GYN, 2026.)

But the details that didn't make the headlines matter: the women in WHI were older on average — around 63 and many were well past the timing window; it mostly tested one specific combo, not the full range of modern options; in the estrogen-alone group (women without a uterus), breast cancer incidence actually went down; and the increased risks were real but small in absolute terms, applied across all ages and formulations even though the study population skewed old. (Source: FDA, 2026; NCI.)

So the science was sound; the interpretationgot overstretched. That mismatch is precisely what regulators set out to fix in 2026 — which is the next section. The takeaway isn't “MHT is risk-free now.” It's that the risks are real, manageable for many people, and finally being described in proportion.

Your situation is unique. The safest read on your personal risk is one a clinician does with your full history in front of them.

What did the FDA change about hormone therapy warnings in 2026?

On February 12, 2026, the FDA approved label changes that removed warnings about cardiovascular disease, breast cancer, and probable dementia from the strongest “boxed warning” on the first batch of six menopausal hormone therapy products. The FDA kept the endometrial-cancer boxed warning for systemic estrogen-alone products. The change is rolling out across more than 20 products. This did not make MHT risk-free — the risk information stayed in the regular label rather than disappearing.

Sources: FDA, 2026; Society of Gynecologic Oncology, 2026; AP, 2026.

The HRT Index 2026 FDA Change Ledger

The first batch named six specific products:

The HRT Index First-Batch Product List

Source: FDA updated prescribing-information list, 2026. The systemic estrogen-alone products — Divigel, Cenestin, and Enjuvia — keep the endometrial-cancer boxed warning.

What it means for you (and what it doesn't)

• It means the conversation is shifting from fear-first to balance-first. The old black-box label scared off people who might have benefited.
• It does not mean hormones are now safe for everyone, or that you should start without a clinician.
• It does not erase the risks. They were re-sorted into the standard label, not deleted. Read that as “described in proportion,” not “gone.”

For a deeper dive on the FDA label change, see our guide: FDA Removes HRT Warning — What It Means.

What side effects can menopausal hormone therapy cause?

Side effects depend on the product, dose, and route. Estrogen-containing MHT can commonly cause breast tenderness, headache, nausea, bloating, and irregular spotting or bleeding, especially in the first few months, and these often settle as your body adjusts. Some risks — like blood clots — are uncommon but serious, which is why your history and route matter. Any unexplained bleeding, especially bleeding after menopause, should be checked by a clinician rather than written off as a normal side effect.

Sources: FDA prescribing information; Mayo Clinic, 2025.

The HRT Index Side-Effect Split

Side effects vary a lot by how you take it — vaginal estrogen tends to cause fewer whole-body side effects than pills. Many people find the early annoyances ease within a few months. Bleeding that's new, heavy, or happens after menopause is not something to ride out — it gets checked. That single rule protects you more than almost anything else on this page.

How long can you take menopausal hormone therapy?

There's no single time limit for menopausal hormone therapy. How long you stay on it is a decision you revisit with a clinician based on your symptoms, your risks, your goals, and whether you still need it. Many people use it during the years symptoms are most disruptive; people with early or premature menopause may use it longer, often at least until the typical age of menopause.

Sources: The Menopause Society, 2022; FDA, 2026.

For years, the standard line was “lowest dose, shortest time.” That's softened. In its 2026 update, the FDA removed that blanket “shortest duration” advice from the boxed warning, because for many people it was driving decisions out of fear rather than fit. (Source: FDA, 2026.) The modern approach is individual: keep using it as long as the benefits outweigh the risks for you, and reassess on a regular schedule.

• No automatic stop date. There isn't a magic age or year where everyone must quit.
• Regular check-ins. Your clinician should revisit your dose, route, symptoms, and risk picture over time.
• Early menopause is its own case. If menopause came early or was surgical, going without estrogen carries its own risks, so the timeline is usually longer. (Source: The Menopause Society, 2022.)

The honest summary: “how long” isn't a number you'll find on a label. It's a conversation you keep having.

Who is menopausal hormone therapy usually a good fit for?

MHT is most often a fit for people with bothersome menopause symptoms who are healthy enough and close enough to menopause that the benefits are likely to outweigh the risks. The Menopause Society describes a generally favorable balance for healthy, symptomatic women under 60 or within 10 years of menopause who have no reasons to avoid it. That's a population guideline, not a personal green light — your own history still decides.

Source: The Menopause Society, 2022.

Based on the major guidelines, here's the profile that tends to line up well. Think of it as a “this sounds like me” checklist, not a diagnosis.

A few specific groups worth calling out: severe hot flashes/night sweats are the classic, best-supported reason to consider systemic MHT. Mainly vaginal or urinary symptoms lean toward low-dose vaginal estrogen as a simpler conversation. And if menopause came early, the Menopause Society notes that going without estrogen early carries its own risks. (Source: The Menopause Society, 2022.)

Who should not start MHT through a quick online visit?

Some people should not start systemic MHT through a fast online intake or without a closer medical review. Red flags include unexplained vaginal bleeding, a possible pregnancy, or a history of breast or uterine cancer, blood clots, stroke, heart attack, or liver disease. This doesn't always mean “no treatment ever” — it means your starting point should be a clinician who can review the full picture, often in person.

Sources: FDA; Office on Women's Health; Mayo Clinic, 2025.

The HRT Index Red-Flag Checklist — disclose these before any MHT conversation:

• Unexplained vaginal bleeding (especially any bleeding after menopause) — this needs to be checked out first, before hormones enter the picture.
• A history of breast cancer or uterine/endometrial cancer.
• A history of blood clots (DVT or pulmonary embolism), stroke, or heart attack.
• Liver disease.
• A known bleeding disorder.
• A past allergic reaction to hormone therapy or to an ingredient in the product.
• High triglycerides or a history of gallbladder disease — especially relevant if oral (pill) estrogen is being considered.
• Pregnancy or the possibility of pregnancy.
• A complicated or high-risk cardiovascular history.

If you checked any of those, please don't try to route around them with a five-minute online form. Start with a clinician — often an in-person one — who can look at the whole picture.

Our one honest admission

A fast, convenient online prescription is the wrong front door for some people. If your history includes unexplained bleeding, certain cancers, clots, stroke, heart attack, or liver disease, the speed that makes telehealth great becomes a liability. But if your symptoms are typical and your history is straightforward, that same convenience is a genuine advantage. The point isn't that online care is bad. It's that the right door depends on your situation.

Do you need blood tests before starting menopausal hormone therapy?

Often, no. For most people over 45 with typical menopause or perimenopause symptoms, clinicians can diagnose the menopause transition from your age, symptoms, and cycle changes — without hormone blood tests. Blood tests still matter in specific cases: if you're under 45, if menopause came early, if your bleeding is abnormal, or if something like thyroid disease or anemia needs to be ruled out.

Sources: NICE; ACOG.

Many assume you need a lab panel to “prove” you're in menopause. Usually you don't. The reason: FSH (follicle-stimulating hormone) bounces around during perimenopause — high one week, normal the next. A single FSH test can easily mislead. That's why guidelines say not to lean on it for routine diagnosis in women over 45.

The HRT Index Lab-Test Guide

What this means for online care

Some telehealth providers require lab work before prescribing; others don't. Neither is automatically right or wrong — it depends on your situation and the provider's model. It's a real difference worth knowing exists before you choose where to go.

What are the non-hormonal alternatives if MHT isn't a fit?

If MHT isn't appropriate or you'd rather not take hormones, there are FDA-approved non-hormonal options, especially for hot flashes. Two newer prescription drugs — fezolinetant (Veozah), approved in 2023, and elinzanetant (Lynkuet), approved in 2025 — target the brain pathway behind hot flashes without estrogen. A low-dose form of paroxetine (Brisdelle) is also FDA-approved for hot flashes. For vaginal symptoms, non-hormonal moisturizers and lubricants can help.

Source: FDA prescribing information.

The HRT Index Non-Hormonal Options Snapshot

These matter most for people who can't take estrogen, such as many breast cancer survivors— because they contain no hormones, they sidestep the estrogen-related concerns. Lifestyle steps — keeping cool, layering, identifying triggers — can take the edge off too. For moderate-to-severe symptoms, they're usually a supplement, not a substitute.

What does starting menopausal hormone therapy actually involve?

Starting MHT usually means a clinician reviews your symptoms, menstrual and uterus history, medications, and risk factors, then discusses options — which could be systemic MHT, local therapy, a non-hormonal route, more testing, in-person evaluation, or no prescription at all. If you do start, follow-up matters: dose, side effects, bleeding, and your risk-benefit balance get reassessed over time.

Source: Mayo Clinic, 2025.

It's a process, not a vending machine. Here's the path, step by step.

1. Track your symptoms. Write down what's actually happening: hot flashes, night sweats, sleep, mood, vaginal dryness, pain with sex, urinary changes, and how your cycles have shifted. Specifics beat “I just feel off.”
2. Know your uterus status. Do you still have your uterus? Any hysterectomy, ablation, or IUD? This single fact shapes the whole prescription.
3. Review your red flags. Run through the checklist: cancer, clot, stroke, heart, liver, bleeding disorder, pregnancy. Be ready to disclose all of it.
4. Choose a route with your clinician. Pill vs. patch vs. gel vs. spray vs. local vaginal options — matched to your symptoms, history, and preferences.
5. Follow up and adjust. This isn't “set it and forget it.” Expect to revisit side effects, any bleeding, how well it's working, your screenings, and whether the plan still fits.

Online vs. in-person menopause care — how should you choose?

Online (telehealth) menopause care can be a convenient, legitimate way to discuss MHT if your symptoms are typical and your history is straightforward. In-person care is the better starting point if you have unexplained bleeding, a complex health history, cancer or clot concerns, or you need a physical exam. The safest choice matches your risk profile — not whichever option has the fastest checkout.

The HRT Index Care-Setting Decision Guide

Telehealth has genuinely widened access to menopause care — that's a real win. But “fast” and “right” aren't the same thing. We're The HRT Index — comparing online options is literally what we do — but on a “what is MHT” page, our job is to help you understand the medicine first. When you're actually ready to compare providers, see our best online HRT providers guide.

What questions should you ask before starting MHT?

The best MHT conversation starts with specific questions, not a vague request for “hormones.” Ask which symptom the treatment targets, whether it's systemic or local, whether it's FDA-approved or compounded, whether you need a progestogen, which risks matter for your history, and when you'll reassess.

Walking in with the right questions changes everything. Here's the script we'd hand a friend.

Copy those. Paste them into your phone. Bring them to the visit.

The bottom line on menopausal hormone therapy

Consider discussing menopausal hormone therapy with a licensed clinician if menopause symptoms are disrupting your life and you want to understand your hormone and non-hormone options. Be more cautious — and likely start with in-person or specialist care — if you have red flags like unexplained bleeding, a history of certain cancers, clots, stroke, heart disease, or liver disease. MHT isn't a purchase to rush. It's a medical decision you make with better questions.

You're probably a good fit to explore MHT if:your symptoms are bothersome, you're under 60 or within 10 years of menopause, your history is clean, and you want a clinician-guided decision. For a lot of people in that spot, MHT is one of the most effective tools there is — and the 2026 label changes mean it's finally being described in proportion instead of fear.

You should pump the brakes if:you're chasing anti-aging, weight loss, or a guaranteed brain boost, or you're trying to skip medical screening. And if you have any red flags, your first stop is a clinician who can see the whole picture — not a fast online start.

Either way, the move is the same: get clear on your symptoms, know your uterus status, list your history, and ask better questions. That's how you end up with a decision that's actually yours.

Frequently asked questions about menopausal hormone therapy

Short, direct answers — with the deeper dives linked above.

What we actually verified for this page

We don't expect you to take our word for it. Here's exactly what we checked, and against what.

• The 2026 FDA label change — confirmed against the FDA's February 12, 2026 announcement and its updated prescribing-information list. We verified what was removed (cardiovascular, breast cancer, dementia from the boxed warning), what was kept (endometrial-cancer warning for systemic estrogen-alone), the six first-batch products, and that the rollout spans 20+ products. Re-checked June 15, 2026.
• The non-hormonal drug facts — confirmed against the FDA prescribing information for Veozah (boxed warning for liver injury; liver testing before, monthly for 3 months, then at 6 and 9 months) and Lynkuet (hepatic transaminase warning; baseline bloodwork plus a 3-month recheck; not for use in pregnancy), plus Brisdelle's approved use.
• The timing window and benefit-risk balance — confirmed against The Menopause Society's 2022 Hormone Therapy Position Statement.
• Bioidentical vs. compounded — confirmed against the FDA's compounding guidance, the National Cancer Institute, ACOG, and the National Academies.
• The progesterone/uterus rule — confirmed against Mayo Clinic, NCI, and the FDA's retained endometrial-cancer warning.
• Blood-test guidance — confirmed against NICE and ACOG.

If any of this changes — and the FDA rollout is still in motion — we update the page and the “last verified” date.

About this guide

Who wrote it:The HRT Index editorial team. The HRT Index is an independent comparison resource for HRT telehealth providers. We don't use fake authors, and we don't slap a “medically reviewed by” badge on our work to borrow authority we didn't earn.

How we made it:We pulled current guidance from the FDA (including drug labels), The Menopause Society, ACOG, the National Cancer Institute, the Office on Women's Health, Mayo Clinic, and Cleveland Clinic, then translated the recurring medical decision points into plain English — including original tools like our Symptom-to-Route Map, Bioidentical Clarity Table, and Timing Window Framework.

Why it exists: Most pages define MHT and then leave you with the same practical questions: Which type fits me? What risks actually matter? What do I ask next? We built this to answer all three in one place.

Last verified: June 15, 2026.

Sources

• U.S. Food and Drug Administration — “FDA Approves Labeling Changes to Menopausal Hormone Therapy Products” (Feb 12, 2026); “Menopausal Hormone Therapies with Updated Prescribing Information” (updated Feb 12, 2026); prescribing information for VEOZAH (fezolinetant) and LYNKUET (elinzanetant). fda.gov
• The Menopause Society (formerly NAMS) — 2022 Hormone Therapy Position Statement, Menopause 29(7):767–794. menopause.org
• ACOG — Clinical Consensus on compounded bioidentical menopausal hormone therapy; “Hormone Therapy for Menopause” patient guidance. acog.org
• National Cancer Institute — “Menopausal Hormone Therapy and Cancer.” cancer.gov
• Office on Women's Health — “Menopause Treatment”; “Menopause: Medicines to Help You.” womenshealth.gov
• Mayo Clinic — “Hormone therapy: Is it right for you?” mayoclinic.org
• Cleveland Clinic — “Hormone Therapy for Menopause Symptoms.” my.clevelandclinic.org
• Society of Gynecologic Oncology — statement on the retained endometrial-cancer warning (2025–2026). sgo.org
• National Academies of Sciences, Engineering, and Medicine — guidance restricting non-FDA-approved compounded bioidentical hormones to specific circumstances. nationalacademies.org
• NICE — menopause diagnosis guidance (FSH testing not routine over 45). nice.org.uk